Description

Product Description

Rituximab solution (CAS 174722-31-7) is a high-purity, research-grade monoclonal antibody preparation designed for advanced immunology, oncology, and cell-based experimentation. As a chimeric anti-CD20 antibody, rituximab solution is widely utilized for studying B-cell biology, immune depletion mechanisms, antibody-mediated cytotoxicity, and tumor microenvironment remodeling. In research laboratories, rituximab solution provides consistent molecular activity, stable antibody structure, and reproducible binding affinity, making it a preferred reference reagent for B-cell–targeted investigations. Researchers choose rituximab solution for its reliability, validated batch specifications, and ability to deliver controlled, quantifiable CD20 engagement across multiple experimental systems.

Rituximab solution (CAS 174722-31-7) plays a critical role in preclinical studies investigating B-cell depletion pathways. Its mechanism involves binding to CD20 on B lymphocytes, allowing researchers to model antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and direct apoptosis induction. The solution format enables precise dosing, rapid integration into in vitro assays, and controlled delivery in in vivo models without the need for additional solubilization steps. This convenience enhances reproducibility and supports high-throughput screening, immune response modeling, and B-cell–driven disease investigations.

In molecular and translational research, rituximab solution is frequently used to examine B-cell dynamics, lymphoid tissue architecture, and immunotherapy-driven cell population shifts. Because CD20 expression is restricted to pre-B and mature B lymphocytes, rituximab provides the ideal tool for mapping B-cell lineage activity, studying depletion kinetics, and analyzing immune compensation patterns. Its well-defined antigen specificity ensures stable experimental outcomes, enabling scientists to compare activity across batches and between experimental conditions with high confidence.

The high stability and controlled composition of rituximab solution (CAS 174722-31-7) also make it essential for evaluating drug resistance pathways, Fc-receptor interactions, and synergistic effects with chemotherapeutic or immunomodulatory agents. In tumor immunology, the solution is used to model antibody-based therapeutic strategies, study lymphoma cell signaling, and characterize tumor–immune interactions in microenvironmental settings. Its flexibility allows incorporation into flow cytometry depletion protocols, in vivo B-cell reduction studies, cell signaling analyses, and combination-therapy design frameworks.

Overall, rituximab solution remains a cornerstone reagent for laboratories focused on B-cell biology, immunotherapy, hematological malignancies, and targeted immune modulation. With its high purity, consistent activity, and reproducible performance, it empowers researchers to conduct precise, mechanistic, and translational studies. Whether used in fundamental immunology, oncology pipelines, or advanced therapeutic modeling, rituximab solution (CAS 174722-31-7) provides a dependable platform for long-term, high-impact scientific discovery.

Product Specifications

This Rituximab solution (CAS 174722-31-7) is manufactured under strictly controlled laboratory conditions to ensure uniformity, structural integrity, and high binding fidelity to CD20 antigens. Researchers rely on its verified ≥98% purity level, which significantly enhances assay reproducibility in immunology, oncology, and B-cell depletion experiments. Each batch undergoes rigorous analytical verification, including HPLC, SDS-PAGE, and LC–MS profiling, ensuring that the rituximab solution delivered to laboratories maintains its expected structural conformation and biological activity.

The solution format eliminates the variability associated with reconstituted antibodies, providing researchers with a precisely formulated, ready-to-use reagent. By offering multiple concentration options and detailed buffer specifications, this rituximab solution supports diverse applications ranging from cell-based assays and depletion studies to in vivo immune modulation experiments. The stabilizing buffer system helps maintain antibody functionality during storage and use, minimizing degradation or aggregation that could otherwise impact experimental reliability.

All rituximab solution (CAS 174722-31-7) vials are sealed under sterile conditions to prevent contamination and ensure safety in bioscience workflows. Packaging options are available from small vials suitable for routine in vitro experimentation to bulk volumes intended for large-scale institutional research programs. Each shipment includes a complete documentation package, allowing seamless integration into GLP or academic research protocols.

The storage guidelines—typically 2–8°C or –20°C depending on formulation—ensure long-term stability while preserving antigen-binding fidelity. Researchers are encouraged to avoid freeze–thaw cycles to maintain optimal performance. With its combination of purity, consistency, and controlled formulation, rituximab solution remains a highly dependable reagent for advanced research applications involving B-cell immunology, CD20 pathway studies, and preclinical immunotherapy modeling.

Mechanism of Action

Rituximab solution (CAS 174722-31-7) functions through a well-characterized and highly targeted mechanism centered on the CD20 antigen, a transmembrane protein expressed on pre-B cells and mature B lymphocytes. When rituximab binds to CD20, it forms a stable antigen–antibody complex that triggers multiple cytotoxic pathways. This precise targeting allows researchers to model B-cell depletion, immune modulation, and antibody-based therapeutic strategies in both in vitro and in vivo systems with high reproducibility and mechanistic clarity.

One of the primary mechanisms is antibody-dependent cellular cytotoxicity (ADCC). After rituximab attaches to CD20, the Fc region of the antibody recruits effector cells such as NK cells and macrophages. These effector cells recognize the Fc fragment via Fcγ receptors and initiate targeted killing of CD20-expressing cells. In research environments, ADCC is commonly quantified to study immune effector function, Fc-receptor signaling, and differential immune cell activation.

Rituximab solution (CAS 174722-31-7) also induces complement-dependent cytotoxicity (CDC). Upon binding to CD20, rituximab activates the classical complement cascade, leading to membrane attack complex (MAC) formation and subsequent lysis of B cells. This mechanism is frequently analyzed in complement activation assays, lymphoma cytotoxicity experiments, and studies comparing complement sensitivity among cell subsets.

A third mechanism involves direct induction of apoptosis. Rituximab binding alters calcium flux, disrupts B-cell receptor (BCR) signaling, and promotes caspase activation. These intracellular events trigger mitochondrial depolarization and apoptotic cell death, making rituximab an ideal tool for studying programmed cell death pathways, B-cell survival circuits, and tumor sensitivity profiling.

Across these mechanisms—ADCC, CDC, and apoptosis—rituximab solution provides a robust model system for investigating B-cell biology, immune clearance, and targeted immunotherapy development. Its specificity for CD20 ensures precise mechanistic dissection and consistent experimental performance across preclinical research models.

Applications

Rituximab solution (CAS 174722-31-7) is widely applied in advanced immunology, oncology, and translational research due to its highly specific binding to the CD20 antigen on B lymphocytes. In immunology research, rituximab is routinely used to model B-cell depletion, enabling scientists to study immune regulation, adaptive immune reshaping, antigen presentation dynamics, and B-cell–dependent cytokine networks. Its predictable activity makes it a reliable tool for exploring autoimmune pathways, tolerance induction, and immune memory disruption in controlled laboratory settings.

In oncology research, rituximab solution plays a central role in the study of B-cell malignancies such as lymphoma and chronic lymphocytic leukemia. Researchers use rituximab to examine tumor sensitivity, resistance mechanisms, microenvironmental interactions, and synergistic effects when combined with cytotoxic agents, kinase inhibitors, or immune-checkpoint modulators. Its ability to trigger ADCC, CDC, and apoptosis also allows experimentation on antibody-mediated cytotoxicity and the engineering of improved CD20-targeted therapeutics.

Rituximab solution (CAS 174722-31-7) is further utilized in cell-based and molecular pathway investigations, including Fc-receptor signaling, complement activation mapping, and apoptosis-related biochemical studies. Flow cytometry–based depletion, B-cell tracking, and CD20 pathway modulation experiments benefit from its reproducible binding affinity and well-defined antigen specificity. Additionally, rituximab is commonly integrated into combination-therapy modeling to evaluate how targeted antibodies influence cell proliferation, survival pathways, and immunomodulatory responses.

In translational and preclinical setups, rituximab solution supports the development of monoclonal antibody platforms, biosimilar characterization, and efficacy prediction models. Its stable solution formulation simplifies assay preparation and ensures consistent dosing across replicates. Overall, rituximab solution (CAS 174722-31-7) remains a foundational reagent for B-cell depletion studies, therapeutic modeling, and high-impact immunological research.

Research Models

Rituximab solution (CAS 174722-31-7) is widely integrated into a diverse range of preclinical research models designed to investigate B-cell biology, immunotherapy mechanisms, and targeted antibody responses. In in vitro models, rituximab is frequently applied to CD20-positive cell lines, including lymphoma and B-lymphoblastoid models, to assess antibody–antigen interactions, cytotoxicity pathways, complement activation, and Fc-receptor signaling. These controlled cellular systems allow researchers to quantify ADCC, CDC, and apoptosis induction with high precision, making them essential tools for mechanistic and comparative antibody studies.

In animal research models, rituximab solution is commonly used in xenograft and humanized mouse systems to replicate B-cell depletion dynamics and evaluate immune effector function. Human CD20-expressing mouse strains or mice engrafted with human lymphoma cells provide robust platforms for assessing tumor regression, immune modulation, and therapeutic combination strategies. These models enable researchers to observe rituximab’s in vivo pharmacodynamics, depletion kinetics, and immunological downstream effects in a controlled and reproducible environment.

Rituximab solution (CAS 174722-31-7) is also employed in autoimmunity and immune-regulation models, where selective removal of B-cell populations helps elucidate the role of these cells in disease progression, antigen presentation, and inflammatory signaling. Models of rheumatoid arthritis, systemic autoimmune responses, and antibody-mediated disorders often rely on rituximab to dissect B-cell–dependent mechanisms and to analyze shifts in T-cell activity and cytokine production following depletion.

Additionally, biosimilar development and therapeutic optimization models routinely utilize rituximab solution to benchmark bioactivity, binding affinity, resistance pathways, and Fc-mediated effector functions. These systems are critical for validating new monoclonal antibody formats and for engineering next-generation CD20-targeted agents.

Overall, rituximab solution supports a comprehensive spectrum of research models—from cellular assays and humanized mice to immunopathology and therapeutic engineering—providing consistent and reliable performance for dissecting CD20-mediated immune processes.

Experimental Design Considerations

Designing experiments with Rituximab solution (CAS 174722-31-7) requires careful attention to concentration, exposure duration, cell type selection, and downstream analytical endpoints to ensure reliable and reproducible outcomes. Because rituximab operates through CD20 engagement, researchers must first confirm CD20 expression levels using flow cytometry or immunoblotting. This verification step ensures proper interpretation of antibody-dependent effects and minimizes confounding results in mixed-cell populations. Additionally, appropriate controls—including isotype-matched antibodies and CD20-negative cell lines—should be incorporated to differentiate specific cytotoxic responses from nonspecific background activity.

For in vitro systems, optimizing dose–response curves is essential for understanding ADCC, CDC, and apoptosis pathways. Rituximab solution concentration should be calibrated according to CD20 density, effector-to-target ratios (E:T), complement availability, and assay sensitivity. Researchers should consider kinetic sampling at multiple time points to capture early signaling events, Fc-receptor engagement, and delayed apoptotic responses. Complement source variability may influence cytotoxic outcomes, so consistent complement batches or heat-inactivation controls are recommended to standardize CDC assays.

In vivo experimental design requires additional considerations, such as dosing regimen, route of administration, and immune system compatibility with rituximab’s Fc-mediated mechanisms. Humanized mouse models expressing human CD20 and Fcγ receptors provide the most accurate representation of rituximab activity. Investigators should monitor B-cell depletion kinetics, immune-cell population shifts, and cytokine signatures to build a comprehensive mechanistic profile. Body weight, organ histology, and serum biomarkers should also be included for safety and mechanistic correlation.

Batch-to-batch consistency is ensured through COA verification; however, researchers should still perform small-scale pilot tests when transferring protocols to new study designs. To maintain antibody integrity, handling practices must minimize freeze–thaw cycles and ensure appropriate storage conditions. Proper experimental design with rituximab solution (CAS 174722-31-7) enables precise modeling of CD20-targeted mechanisms and supports robust, high-fidelity analysis in immunology, oncology, and therapeutic development research contexts.

Laboratory Safety & Handling Guidelines

Handling Rituximab solution (CAS 174722-31-7) requires strict adherence to laboratory safety protocols due to its biological activity as a monoclonal antibody targeting CD20. Although intended solely for research, improper handling can lead to unintended exposure or contamination. All personnel should wear appropriate personal protective equipment (PPE), including gloves, lab coats, and eye protection, when preparing, pipetting, or transferring the solution. Work should be conducted in a biosafety cabinet or equivalent containment environment to prevent aerosol formation and maintain sterility.

Accidental exposure through skin contact or inhalation, though unlikely, should be treated promptly by washing affected areas thoroughly and following institutional emergency procedures. Instruments and work surfaces should be disinfected with suitable agents, and all contaminated materials—including pipette tips, tubes, and vials—should be disposed of in biohazard containers according to local regulations. Use dedicated glassware or plasticware to avoid cross-contamination between experiments or different batches.

Storage conditions are critical to maintain the structural integrity and biological activity of rituximab. Store the solution at 2–8°C for short-term use or at –20°C for long-term storage, avoiding repeated freeze–thaw cycles. Vials should remain tightly sealed and protected from light, moisture, and temperature fluctuations. Label all containers clearly with product name, CAS number, and date of receipt to prevent accidental misuse.

When preparing dilutions or experimental treatments, avoid creating aerosols and ensure solutions are mixed gently. For any waste disposal, follow institutional protocols for biologically active reagents, segregating liquids and solids appropriately. Keep detailed records of batch number, expiration date, and COA for traceability.

By following these laboratory safety and handling guidelines, researchers can safely utilize Rituximab solution (CAS 174722-31-7) in preclinical studies while maintaining experimental integrity, reproducibility, and compliance with regulatory standards. Proper practices reduce risk to personnel and ensure consistent experimental outcomes across immunology and oncology research applications.

Integration with Multi-Omic & Computational Studies

Rituximab solution (CAS 174722-31-7) provides a versatile platform for integration into multi-omic and computational research workflows, enabling comprehensive mechanistic insights into B-cell biology, CD20 signaling, and immunotherapy responses. In preclinical studies, rituximab is often combined with transcriptomic profiling to identify gene expression changes triggered by B-cell depletion, apoptosis induction, or Fc-mediated immune engagement. Differential expression analyses can reveal pathways related to cell cycle regulation, immune modulation, and antibody-mediated cytotoxicity, which are critical for understanding both efficacy and resistance mechanisms.

Proteomics and phosphoproteomics approaches complement transcriptomics by quantifying protein abundance and post-translational modifications following rituximab exposure. This allows researchers to evaluate signaling cascades, apoptotic pathways, and immune effector activation with high resolution. Integration of these datasets can generate network models illustrating how rituximab modulates intracellular and intercellular signaling in B cells and surrounding immune populations. Metabolomic profiling further elucidates effects on energy metabolism, nucleotide pools, and oxidative stress, offering a holistic view of rituximab’s mechanistic impact.

Computational tools such as systems biology modeling, pathway enrichment, and network analysis can synthesize multi-omic data into predictive frameworks. These models help researchers identify potential biomarkers, simulate dose-response effects, and optimize experimental parameters. Machine learning algorithms can further refine predictions by detecting subtle correlations or patterns in large datasets, enhancing the predictive value of preclinical studies.

Rituximab’s solution format ensures precise dosing and reproducibility, which is crucial when integrating omics datasets across experiments. Consistency between batches enables high-fidelity comparisons and longitudinal studies, allowing researchers to correlate molecular, cellular, and functional outcomes. Combined, multi-omic analyses and computational modeling provide a systems-level understanding of B-cell depletion, immune regulation, and therapeutic mechanisms.

By leveraging Rituximab solution (CAS 174722-31-7) in multi-omic and computational studies, researchers can uncover complex immune signaling networks, predict treatment responses, and design rational combination strategies. This integration supports robust preclinical research in immunology, oncology, and therapeutic antibody development, ultimately bridging molecular mechanisms with translational applications.

Side Effects (Research Observations)

Rituximab solution (CAS 174722-31-7) is widely used in preclinical research to study B-cell depletion, CD20-targeted mechanisms, and immune modulation. While primarily a research reagent, careful observation of biological effects in model systems is critical to understanding both intended and off-target responses. In in vitro studies, rituximab reliably induces apoptosis, ADCC, and CDC in CD20-positive cells. These effects are considered part of the intended mechanism; however, high concentrations or prolonged exposure can occasionally result in modest cytotoxicity in non-target cells or alterations in cellular signaling pathways, highlighting the importance of precise dosing and experimental controls.

In animal models, rituximab administration may lead to transient physiological changes, including alterations in circulating B-cell populations, temporary cytokine shifts, and mild immune cell redistribution. These effects reflect the antibody’s potency in modulating immune networks rather than classical toxicity. Researchers have observed reversible changes in organ weights, spleen cellularity, and lymphoid tissue architecture when studying B-cell depletion, particularly in murine and humanized mouse models. Such responses are valuable for modeling therapeutic activity but should be carefully monitored to distinguish mechanistic effects from experimental artifacts.

Long-term preclinical studies with rituximab solution occasionally demonstrate modest immunological or hematological variations, such as reduced B-cell counts, transient lymphopenia, or altered serum immunoglobulin levels. These observations correlate with the antibody’s CD20-targeted activity and are typically reversible after cessation of treatment. Importantly, rituximab does not generally induce off-target cytotoxicity in non-B-cell populations at research-appropriate concentrations, but researchers are encouraged to include proper negative controls, dose titrations, and replicate analyses to ensure robust interpretation of results.

Overall, the side effects observed in preclinical research using rituximab solution are closely tied to its intended biological activity as a chimeric monoclonal antibody. By adhering to optimized experimental design, carefully monitoring physiological and cellular responses, and maintaining appropriate dosing protocols, researchers can leverage rituximab’s potent mechanisms while minimizing unintended off-target effects. These observations provide essential insights for B-cell depletion modeling, immune pathway analysis, and translational research applications.

Keywords

Rituximab solution, CAS 174722-31-7, monoclonal antibody research, B-cell depletion reagent, chimeric IgG1 antibody, oncology pathway analysis, immunopharmacology reagent, antibody-based inhibition, factory direct supply, low-price wholesale antibody.

Shipping Guarantee

Global express delivery with full tracking ensures timely transport of Rituximab Solution (CAS 174722-31-7) to research institutions worldwide. Temperature-controlled cold-chain protection maintains structural integrity and prevents denaturation during shipping. Each batch is sealed in moisture-resistant sterile primary packaging with secondary insulated containers. A COA with batch-specific analytical data is included to guarantee reproducibility and compliance with laboratory quality systems.

Trade Assurance

Factory-level production enables consistent large-volume output with strict quality monitoring. Researchers placing bulk or recurring orders receive validated documentation, including COA, HPLC chromatograms, LC–MS profiles, and endotoxin reports. Institutional clients can use secure procurement contracts supporting long-term supply continuity. Wholesale pricing structures are available for distributors, CROs, and biotech labs requiring scalable antibody solutions.

Payment Support

Multiple international payment methods are accepted, including TT, LC, corporate invoice, bank transfer, and PayPal. Researchers purchasing sample quantities or bulk lots can choose flexible billing terms tailored to laboratory procurement workflows. Universities and institutes may request invoice-based payment with verified documentation for institutional purchasing systems.

Disclaimer

For research use only. Not intended for human or veterinary application. Rituximab Solution must be handled by trained laboratory personnel following institutional biosafety standards. This product is not a therapeutic drug and should not be used outside controlled experimental environments.

References 

1. Complement‑induced cell death by rituximab depends on CD20 expression level and acts complementary to antibody‑dependent cellular cytotoxicity. PubMed

2. Rituximab (anti‑CD20) therapy of B-cell lymphomas: direct complement killing is superior to cellular effector mechanisms. PubMed

3. In vitro mechanisms of action of rituximab on primary non‑Hodgkin lymphomas. PubMed

4. Opportunities and limitations of B cell depletion approaches in SLE. PubMed

5. Monoclonal Antibodies for B‑Cell Lymphomas: Rituximab and Beyond. ASH Education Program. ASH Publications